| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Ann Thorac Surg 1997;64:1585-1591
© 1997 The Society of Thoracic Surgeons
Departments of Thoracic Surgery and Human Biopathology, University of Rome "La Sapienza," Rome, Italy
Background. Thymomas are a heterogeneous group of tumors. Treatment of invasive lesions is not well standardized. The aim of this study is to propose a clinicopathologically based protocol for multimodality therapy.
Methods. Between 1965 and 1988, we operated on 83 patients with thymoma who did not receive standardized adjuvant therapy. In 1989, on the basis of the retrospective analysis of the data, we started a multimodality therapy protocol and used it for 65 patients. Twelve patients had medullary thymoma (11 stage I and 1 stage II), 13 had mixed type (6 stage I and 7 stage II), and 40 had cortical thymoma (4 stage I, 11 stage II, 12 stage III, and 13 stage IV). We considered three groups. Group I (n = 18 patients), benign thymoma, included stage I and II medullary and stage I mixed thymomas; radical resection with no adjuvant therapy was performed. Group II (n = 22), invasive thymoma, included stage I and II cortical and stage II mixed thymomas; postoperative chemotherapy plus radiotherapy was always administered. Group III (n = 25), malignant thymoma, comprised stage III and IV cortical thymomas and stage III mixed thymomas; resectable stage III lesions were removed, and highly invasive stage III and stage IV lesions underwent biopsy, neoadjuvant chemotherapy, and surgical resection; postoperative chemotherapy and radiotherapy was administered to all patients.
Results. The 8-year survival rate for patients in stages I, II, III, and IV was 95%, 100%, 92%, and 68%, respectively. Patients with medullary thymoma had a 92% 8-year survival rate; those with mixed type, 100%; and those with cortical thymoma, 85%. Group I had an 8-year survival rate of 94%; group II, 100%; and group III, 76%. Survival was compared with that of patients operated on before 1989: differences were not significant for group I; survival improved in group II (100% versus 81%; p = not significant); and group III showed significant improvement (76% versus 43%; p < 0.049).
Conclusions. Multimodality treatment with neoadjuvant chemotherapy and adjuvant chemotherapy plus radiotherapy may improve the results of radical resection and the survival of patients with invasive and malignant thymoma.
Related Article
Ann. Thorac. Surg. 1997 64: 1591-1592.
This article has been cited by other articles:
|
|
 |
|
  Y. Ishikawa, H. Matsuguma, R. Nakahara, H. Suzuki, A. Ui, T. Kondo, Y. Kamiyama, S. Igarashi, K. Mori, T. Kodama, et al. Multimodality therapy for patients with invasive thymoma disseminated into the pleural cavity: the potential role of extrapleural pneumonectomy. Ann. Thorac. Surg., September 1, 2009; 88(3): 952 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tomaszek, D. A. Wigle, S. Keshavjee, and S. Fischer Thymomas: Review of Current Clinical Practice. Ann. Thorac. Surg., June 1, 2009; 87(6): 1973 - 1980. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Detterbeck Clinical Value of the WHO Classification System of Thymoma Ann. Thorac. Surg., June 1, 2006; 81(6): 2328 - 2334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Suzuki, H. Sasaki, O. Kawano, K. Endo, H. Haneda, H. Yukiue, Y. Kobayashi, M. Yano, and Y. Fujii Expression and Mutation Statuses of Epidermal Growth Factor Receptor in Thymic Epithelial Tumors Jpn. J. Clin. Oncol., June 1, 2006; 36(6): 351 - 356. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. D. Wright, J. C. Wain, D. R. Wong, D. M. Donahue, H. A. Gaissert, H. C. Grillo, and D. J. Mathisen Predictors of recurrence in thymic tumors: Importance of invasion, World Health Organization histology, and size J. Thorac. Cardiovasc. Surg., November 1, 2005; 130(5): 1413 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Venuta, T. de Giacomo, C. Andreetti, and G. Furio Coloni Transsternal thymoma resection MMCTS, April 25, 2005; 2005(0425): 182. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rea, G. Marulli, R. Girardi, L. Bortolotti, A. Favaretto, A. Galligioni, and F. Sartori Long-term survival and prognostic factors in thymic epithelial tumours Eur. J. Cardiothorac. Surg., August 1, 2004; 26(2): 412 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. C. Detterbeck and A. M. Parsons Thymic tumors Ann. Thorac. Surg., May 1, 2004; 77(5): 1860 - 1869. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Venuta, E. A. Rendina, F. Longo, T. De Giacomo, M. Anile, E. Mercadante, L. Ventura, M. F. Osti, F. Francioni, and G. F. Coloni Long-term outcome after multimodality treatment for stage III thymic tumors Ann. Thorac. Surg., December 1, 2003; 76(6): 1866 - 1872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Refaely, D. A. Simansky, M. Paley, M. Gottfried, and A. Yellin Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread Ann. Thorac. Surg., August 1, 2001; 72(2): 366 - 370. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. B. Johnson, T. Y. Eng, G. Giaccone, and C. R. Thomas Jr. Thymoma: Update for the New Millenium Oncologist, June 1, 2001; 6(3): 239 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Venuta, E. A. Rendina, T. De Giacomo, G. Della Rocca, G. Antonini, A. M. Ciccone, C. Ricci, and G. F. Coloni Thymectomy for myasthenia gravis: a 27-year experience Eur. J. Cardiothorac. Surg., May 1, 1999; 15(5): 621 - 625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Venuta, E. A. Rendina, T. De Giacomo, A. M. Ciccone, and G. F. Coloni Severe postoperative hemorrhage after neoadjuvant chemotherapy for invasive thymoma Ann. Thorac. Surg., September 1, 1998; 66(3): 981 - 982. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |
